2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene

详情介绍：

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS N0.:898566-17-1
Usage: Canagliflozin Intermediates
Molecular Formula:C18H14FIS
Content: 99%min
in stock
other intermediates:5-Iodo-2-methylbenzoic acid [CAS NO.: 54811-38-0]
2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene [CAS NO.:1030825-20-7]
Canagliflozin hemihydrate [CAS NO.:928672-86-0]

Diabetes can be divided into insulin-dependent (type I) and non-insulin dependent (type II), including type II diabetes is most common, accounting for more than90%of diabetic patients.Because the pathogenesis of diabetes complicated mankind has yet to find a cure for, which means that patients need lifelong treatment. As the pathophysiology of diabetes-depth understanding of different pathophysiological aspects of drug development is increasing. sodium-glucose co-transporter is currently developing a new, efficient one of hypoglycemic agents. It inhibits the activity of SGLT-2to enhance incretion activity, thereby reducing blood sugar, diabetes; drug therapy has become the new focus.
For the present,sodium-glucose co-transporter 2(SGLT2) inhibitors have become a potentially new therapeutic approach for the treatment of type 2 diabetes,and they could lower the blood glucose levels by inhibiting glucose reabsorption in the renal proximal tubules.They conclude C-aryl inhibitor,O-aryl inhibitor,S-aryl inhibitor,and N-aryl inhibitor,but C-aryl inhibitor and O-aryl inhibitor are in the hot research.Several SGLT2 inhibitors in development(dapagliflozin,canagliflozin,ASP1941,BI10773,and LX4211) have demonstrated the improvement in glycemic control and weight loss,along with slight adverse effects.
Shanghai Yongzeng Chemical Company limited

Diabetes can be divided into insulin-dependent (type I) and non-insulin dependent (type II), including type II diabetes is most common, accounting for more than90%of diabetic patients.Because the pathogenesis of diabetes complicated mankind has yet to find a cure for, which means that patients need lifelong treatment. As the pathophysiology of diabetes-depth understanding of different pathophysiological aspects of drug development is increasing. sodium-glucose co-transporter is currently developing a new, efficient one of hypoglycemic agents. It inhibits the activity of SGLT-2to enhance incretion activity, thereby reducing blood sugar, diabetes; drug therapy has become the new focus.
For the present,sodium-glucose co-transporter 2(SGLT2) inhibitors have become a potentially new therapeutic approach for the treatment of type 2 diabetes,and they could lower the blood glucose levels by inhibiting glucose reabsorption in the renal proximal tubules.They conclude C-aryl inhibitor,O-aryl inhibitor,S-aryl inhibitor,and N-aryl inhibitor,but C-aryl inhibitor and O-aryl inhibitor are in the hot research.Several SGLT2 inhibitors in development(dapagliflozin,canagliflozin,ASP1941,BI10773,and LX4211) have demonstrated the improvement in glycemic control and weight loss,along with slight adverse effects.
Shanghai Yongzeng Chemical Company limited